GlassScriptPhysician profile
Mohammad Q Khan
NPI 1104892868
$15,952.35
in general payments reported to CMS, 2019-2025
67 companies · $1,717 in 2025
The $1,717 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,691 · 2020: $2,484 · 2021: $3,040 · 2022: $2,064 · 2023: $1,911 · 2024: $2,046 · 2025: $1,717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,673.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,116.91 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,816.98 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,577.53 | 2019-2025 | Jardiance |
| Pfizer INC. | $965.49 | 2019-2025 | |
| Gilead Sciences, INC. | $861.71 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $709.93 | 2019-2025 | Linzess |
| Lilly USA, LLC | $655.99 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Janssen Pharmaceuticals, INC | $577.58 | 2019-2024 | Xarelto, Invega Sustenna, Spravato |
| Allergan, INC. | $479.59 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $461.03 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $451.52 | 2019-2023 | Trintellix |
| Astellas Pharma US INC | $387.05 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $368.35 | 2019-2025 | Gardasil 9, Capvaxive |
| Glaxosmithkline, LLC. | $354.68 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $320.32 | 2023-2025 | Rexulti, Abilify Maintena |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.